Targeting the tumour stroma to improve cancer therapy

KC Valkenburg, AE De Groot, KJ Pienta - Nature reviews Clinical …, 2018 - nature.com
Cancers are not composed merely of cancer cells alone; instead, they are complex
'ecosystems' comprising many different cell types and noncellular factors. The tumour stroma …

[HTML][HTML] Implementing TMB measurement in clinical practice: considerations on assay requirements

R Büttner, JW Longshore, F López-Ríos… - ESMO open, 2019 - Elsevier
Clinical evidence demonstrates that treatment with immune checkpoint inhibitor
immunotherapy agents can have considerable benefit across multiple tumours. However …

Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application

G Lightbody, V Haberland, F Browne… - Briefings in …, 2019 - academic.oup.com
There has been an exponential growth in the performance and output of sequencing
technologies (omics data) with full genome sequencing now producing gigabases of reads …

[HTML][HTML] Gene expression detection assay for cancer clinical use

S Narrandes, W Xu - Journal of Cancer, 2018 - ncbi.nlm.nih.gov
Cancer is a genetic disease where genetic variations cause abnormally functioning genes
that appear to alter expression. Proteins, the final products of gene expression, determine …

Detection of breast cancer by ATR-FTIR spectroscopy using artificial neural networks

RC Tomas, AJ Sayat, AN Atienza, JL Danganan… - PLoS …, 2022 - journals.plos.org
In this study, three (3) neural networks (NN) were designed to discriminate between
malignant (n= 78) and benign (n= 88) breast tumors using their respective attenuated total …

Technical evaluation of commercial mutation analysis platforms and reference materials for liquid biopsy profiling

S Weber, B Spiegl, SO Perakis, CM Ulz, PM Abuja… - Cancers, 2020 - mdpi.com
Molecular profiling from liquid biopsy, in particular cell-free DNA (cfDNA), represents an
attractive alternative to tissue biopsies for the detection of actionable targets and tumor …

Molecular pathway activation–new type of biomarkers for tumor morphology and personalized selection of target drugs

A Buzdin, M Sorokin, A Garazha, M Sekacheva… - Seminars in cancer …, 2018 - Elsevier
Anticancer target drugs (ATDs) specifically bind and inhibit molecular targets that play
important roles in cancer development and progression, being deeply implicated in …

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients

E Papadopoulou, N Tsoulos, K Tsantikidi… - PloS one, 2019 - journals.plos.org
Background Analysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung
Cancer (NSCLC) patients is the most widespread and documented form of" liquid biopsy" …

Clinically relevant fusion oncogenes: Detection and practical implications

M Sorokin, E Rabushko… - Therapeutic …, 2022 - journals.sagepub.com
Mechanistically, chimeric genes result from DNA rearrangements and include parts of
preexisting normal genes combined at the genomic junction site. Some rearranged genes …

Quantitation of molecular pathway activation using RNA sequencing data

N Borisov, M Sorokin, A Garazha, A Buzdin - Nucleic Acid Detection and …, 2020 - Springer
Intracellular molecular pathways (IMPs) control all major events in the living cell. IMPs are
considered hotspots in biomedical sciences and thousands of IMPs have been discovered …